Wednesday, November 26, 2014

Sunstar Expands Horizons to Enhance Efficiency Throughout the Dental Practice



Noted innovator launches efficiency-enhancing “game changers” in both hygiene and periodontology
Chicago, IL, November 25, 2014 —Leading oral healthcare products manufacturer Sunstar Americas will use the Greater New York Dental Meeting to showcase efficiency-enhancing innovations for not only its traditional area of hygiene care, but for periodontal procedures as well. Looking to augment its longstanding heritage as a dental hygiene innovator, Sunstar will spotlight its new Butler® ProphyciencyTM disposable prophy angles, the industry’s only prophy angles that clean and polish without paste. In addition, the company will expand its reach within the dental practice with its launch of a revolutionary, easy-to-handle bone grafting solution aptly named GUIDOR® easy-graft® alloplastic bone grafting system.
Butler® ProphyciencyTM disposable prophy angles, the latest breakthrough in professional dental hygiene pioneered by Sunstar, represent a truly smarter way to clean. They can save hygienists considerable time by eliminating the need to refill the cup in the prophy angle as well as the need for the patient to rinse during a cleaning, by providing much better visibility during cleaning, and by simplifying cleanup between patients due to the lack of paste splatter or mess.
Moreover, Butler® ProphyciencyTM delivers exceptionally versatile cleaning efficacy. Its unique ButlerBloomTM. Contouring Cup is designed to effectively clean and polish interproximally, subgingivally and on all facial and lingual tooth surfaces. It adapts better to follow contours on all tooth surfaces, and it transitions easily from tooth to tooth. One study revealed that 78% of patients who received a ProphyciencyTM prophylaxis preferred it to the traditional procedure. A related study revealed that 71% of dental professionals who used ProphyciencyTM felt that it would be beneficial to their polishing procedure and patient care. In addition, clinical research indicates that ProphyciencyTM delivers significantly superior stain removal than the leading prophy angle brand used in combination with the leading prophy paste.
GUIDOR® easy-graft® is an ultra-efficient bone grafting solution being introduced by Sunstar into the
North American market after years of success in overseas markets. It is a fully resorbable, synthetic bone graft substitute that will appeal to clinicians who seek stability, osteoconductivity and control of placement. With over 250,000 applications worldwide, GUIDOR® easy-graft® is a complete system that can be trusted to predictably and efficiently handle all socket preservation and immediate implant needs.
Each GUIDOR® easy-graft® system is composed of beta-tricalcium phosphate granules coated with a polylactide polymer that are mixed with an N-methyl-2-pyrrolidone liquid activator called BioLinker® to form a permeable, moldable material that hardens to form a stable, porous scaffold. This unique combination of materials in GUIDOR® easy-graft® provides the foundation for exceptionally easy preparation, dispensing and shaping. The porosity of the granule supports material resorption and bone regeneration. A majority of clinicians surveyed said they use GUIDOR® easy-graft® because preparation and placement are simpler and faster than other bone graft materials and because use it does not require a membrane in many cases.
“We feel these two innovations will have a dramatic impact on the efficiency of our valued customers,” said Aaron Pfarrer, Senior Director of Marketing and Professional Relations for Sunstar. “Butler® ProphyciencyTM builds on our rich heritage of enhancing the efficacy and convenience of hygiene care, while GUIDOR® easy-graft® will enable us to bring the same degree of ingenuity to periodontics that we have been bringing to dental hygiene for decades.”
The Butler® ProphyciencyTMand GUIDOR® easy-graft® product lines, and all other Sunstar Americas products, can be viewed at Booth #3828 at the Greater New York Dental Meeting November 30 through December 3, 2014. Additional information about Sunstar Americas professional dental products can be found at us-professional.gumbrand.com.
###
Sunstar Americas
Chicago-based Sunstar Americas, Inc. is a member of the Sunstar Group of companies and provides quality oral care products under the Butler®, GUM® and GUIDOR® brands. Sunstar, a global organization headquartered in Switzerland, has been providing research-based products and services in 90 countries for over 80 years. Sunstar’s mission is to enhance the health and well-being of people everywhere via its four business areas: mouth and body, health and beauty, healthy home, and safety and technology. Please visit us at www.sunstar.com.

Tuesday, November 25, 2014

Join me at the Greater NY Dental Meeting

I will be presenting lectures at the Greater New York Dental Meeting on Sunday at 1pm and 3pm on Accelerated Orthodontics for the GP in the Propel booth 418. On Monday at 9:45am Digital Technology, Managing The Fastest Area of Growth In Your Practice on securing your office data. That lecture will take place on the exhibit floor.

PeriRx, LLC Covering all Bases During Its Greater New York Dental Meeting Debut

 
Company’s Launch of its SaliMark™ OSCC Salivary Test for Oral Cancer
Includes Free CE Course, Free Industry Reception and Free Test Kit

Broomall, PA – November 24,  2014 – PeriRx LLC, a premier developer of breakthrough, non-invasive, oral diagnostic technology, will be making its national debut at booth #1506 during the Greater New York Dental Meeting from Sunday, November 30th  to  Wednesday, December 3rd at the Jacob K. Javits Convention Center in New York City.
“We’re very excited to be making our official debut at the Greater New York Dental Meeting,” said Stephen M. Swanick, CEO and founder of PeriRx, LLC. “We’re using a variety of ways to engage with members of the dental community and tell them about SaliMark™ OSCC, the most clinically-advanced salivary test for oral cancer, which is scheduled to ship before the end of the year.”
Development of this simple-to-use, painless and noninvasive test was based on the strong scientific foundation of NIH-funded research with initial discovery and pre-validation work conducted by Dr. David Wong of the University of California at Los Angeles.  What’s more, more than a decade of National Institute of Dental and Craniofacial Research and National Institute of Health- supported research make SaliMark™ OSCC the world’s most scientifically-validated molecular DNA biomarker test for oral squamous cell carcinoma.
In addition to exhibiting at booth #1506, PeriRx will be introducing SaliMark OSCC in the following ways:
·       Free CE Course: “Salivary Testing for Early Diagnosis of Oral Cancer" (course code #3240) will be given on Sunday November 30th, 2014 at 9am.  Attendees will receive $15.00 lunch voucher at the end of the course which can be used at any Javits restaurant.  Course presenters are Jack Martin, MD, Neil Gottherer, DDS and Mark Cohen, DDS.

·       Free Industry Reception: This press conference for the entire industry will feature some late-breaking research data presented by the PeriRx executive team that further confirms the efficacy of SaliMark OSCC for early oral cancer detection. Several other industry leaders are expected to say a few words regarding the importance of these latest findings.  This free event will take place on Monday, December 1st from 3:00 - 4:00 PM at booth # 5430.
-more-

·       Free SaliMark OSCC Test Kit: Any dental practice owner who pre-registers and creates a PeriRx online ordering account, will receive one free SaliMark test Kit in order to get familiar with the test, the protocol and the lab results. Simply visit http://perirxsecure.com/register.php to register your practice and set up an account.* 
For more information about PeriRx, LLC or its SaliMark OSCC salivary test for oral cancer, visit www.PeriRx.com, call 610-544-3500 or send an email to info@PeriRx.com.
* Not yet approved for sale in the state of New York. New York practice owners who register online will be kept on file and notified immediately when SaliMark is approved for sale and use in their state.

About SaliMark™ OSCC
Development of this simple-to-use, painless and noninvasive test was based on the strong scientific foundation of NIH-funded research with initial discovery and pre-validation work conducted by Dr. David Wong of the University of California at Los Angeles. The SaliMark OSCC test also has the distinction of being the first of its kind assay in the world to aid in the identification and early detection of oral lesions at the highest risk for cancer.  Recently, the SaliMark OSCC test underwent a PRoBE (prospective-specimen-collection, retrospective-blinded-evaluation) design study which is the most rigorous biomarker validation available. In addition, PeriRx successfully completed a validation of the mRNA markers at the University of Michigan, Michigan State University and the St. Johns Providence Health System in Detroit.
About PeriRx LLC:
Based in Broomall, Pennsylvania, PeriRx LLC is a premier developer of breakthrough, non-invasive, oral diagnostic technology that will help clinical professionals detect and treat diseases sooner and enhance the practice of wellness management.  
The company was founded in 2008 to explore, innovate, and develop novel therapeutics or devices focused on the oral inflammatory/systemic connection. The PeriRx executive team consists of CEO and founder Stephen M. Swanick, an entrepreneur and experienced drug and device development professional; Dr. Neil Gottehrer, a practicing dentist; and Dr. Jack Martin, a cardiologist.
PeriRx obtained its patented and patent-pending technologies from inventor Dr. David Wong’s firm RNAmeTRIX and the Regents of the University of California at Los Angeles. PeriRx and RNAmeTrix have ongoing agreements which ensure the continuing research and development necessary to advance product development from clinical trial, through regulatory approval, and into commercialization.

Monday, November 24, 2014

Visual acuity of dentists in their respective clinical conditions

, Volume 18, Issue 9, pp 2055-2058
Date: 31 Jan 2014

Abstract

Objectives

This study examined the impact of age and magnification on the near visual acuity of dentists in their private practice under simulated clinical conditions.

Materials and methods

Miniaturized visual tests were fixed in posterior teeth of a dental phantom head and brought to 31 dentists in their respective private practice. The visual acuity of these dentists (n = 19, ≥40 years; n = 12, <40 300="" a="" acuity="" additional="" and="" available.="" b="" c="" choice="" clinical="" conditions:="" distance="" following="" free="" if="" in="" light="" loupe="" measured="" mm="" natural="" nbsp="" of="" p="" setting="" source="" the="" under="" visual="" was="" years="">

Results

The visual acuity under the different clinical conditions varied widely between individuals. The older group of dentists had a lower median visual acuity value under all clinical conditions. This difference was highly significant for natural visual acuity at a free choice of distance (p < 0.0001). For younger dentists (<40 acuity="" be="" by="" class="a-plus-plus" could="" distance="" em="" eye-object="" improved="" nbsp="" reducing="" significantly="" the="" visual="" years="">p
= 0.001) or by using loupes (p = 0.008). For older dentists (≥40 years), visual acuity could be significantly improved by using loupes (p = 0.0005).

Conclusions

Visual performance decreased with increasing age under the specific clinical conditions of each dentist’s private practice. Magnification aids can compensate for visual deficiencies.

Clinical relevance

The question of whether findings obtained under standardized conditions are valuable for the habitual setting of each dentist’s private practice seems clinically relevant.

Friday, November 21, 2014

Influence of daily immersion in denture cleanser on multispecies biofilm

, Volume 18, Issue 9, pp 2179-2185
Date: 04 Mar 2014

Abstract

Objective

The aim of this study was to evaluate the effect of daily exposure to a denture cleanser on a multispecies biofilm.

Materials and methods

Multispecies biofilms (five bacteria and Candida albicans) were developed for 64.5 h on acrylic resin specimens and randomized into control and experimental groups. In the experimental group, biofilms were immersed in denture cleanser for 3 min/day for seven consecutive days. In the control group, the biofilms were developed with no treatment for the same period. Biofilms from both groups were collected after 1, 4, and 7 days and analyzed for the number of microorganisms and polysaccharide concentrations. Scanning electron microscopy (SEM) and confocal microscopy (CLSM) analyses were performed.

Results

The total microorganism counts and bacterial populations were lower in the experimental group compared to the control group for all of the periods evaluated. However, the C. albicans counts continuously increased in all of the cleanser-exposed biofilms, with abundant hyphae forms on SEM and CLSM images. The polysaccharide concentration was significantly higher in the experimental group after 7 days.

Conclusions

Daily exposure of a multispecies biofilm to a denture cleanser reduces the number of total microorganisms but favors C. albicans development.

Clinical relevance

Daily use of denture cleanser is an effective method for controlling bacteria in biofilm, but it can potentially select C. albicans, an important etiological agent of oral candidosis.

Thursday, November 20, 2014

Six-month results following treatment of aggressive periodontitis with antimicrobial photodynamic therapy or amoxicillin and metronidazole

, Volume 18, Issue 9, pp 2129-2135
Date: 04 Feb 2014

Abstract

Objective

The use of antibacterial photodynamic therapy (aPDT) additionally to scaling and root planing (SRP) has been shown to positively influence the clinical outcomes. However, at present, it is unknown to what extent aPDT may represent a potential alternative to the use of systemic antibiotics in nonsurgical periodontal therapy in patients with aggressive periodontitis (AP). The aim of this study was to evaluate the outcomes following nonsurgical periodontal therapy and additional use of either aPDT or amoxicillin and metronidazole (AB) in patients with AP.

Material and methods

Thirty-six patients with AP displaying at least three sites with pocket depth (PD) ≥6 mm were treated with SRP and either systemic administration of AB for 7 days or with two episodes of aPDT. The following clinical parameters were evaluated at baseline and at 6 months: plaque index (PI), bleeding on probing (BOP), PD, gingival recession (GR) and clinical attachment level (CAL).

Results

Thirty-five patients have completed the 6-month evaluation. At 6 months, mean PD was statistically significantly reduced in both groups (from 5.0 ± 0.8 to 3.0 ± 0.6 mm with AB and from 5.1 ± 0.5 to 3.9 ± 0.8 mm with aPDT (p < 0.001)). AB yielded statistically significantly higher improvements in the primary outcome parameter PD (p < 0.001) when compared to aPDT. The number of pockets ≥7 mm was reduced from 141 to 3 after AB (p < 0.001) and from 137 to 45 after aPDT (p = 0.03). Both therapies resulted in statistically significant reductions in all parameters compared to baseline.

Conclusion

While both treatments resulted in statistically significant clinical improvements, AB showed statistically significantly higher PD reduction and lower number of pockets ≥7 mm compared to aPDT.

Clinical relevance

In patients with AP, the two times application of aPDT in conjunction with nonsurgical periodontal therapy cannot be considered an alternative to the systemic use of amoxicillin and metronidazole.

Wednesday, November 19, 2014

Microbial contamination of laboratory constructed removable orthodontic appliances

, Volume 18, Issue 9, pp 2193-2202

Abstract

Objectives

This study aims to determine whether laboratory constructed removable orthodontic appliances are free from microbial contamination prior to clinical use and to evaluate the dental hospital cross-infection procedures to ensure that patient-derived contamination does not enter the construction process, thereby propagating a cycle of cross-contamination.

Materials and methods

The construction process of removable orthodontic appliances from three individuals was evaluated at every stage, from impression to final delivery of the appliance using molecular microbiological techniques. The bacterial profiles at each stage of appliance construction were obtained using denaturing gradient gel electrophoresis, along with the bacterial profiles of the three participants’ saliva. This enabled the bacterial profiles found at each stage of construction to be compared directly with the saliva of the person for whom the appliance was being constructed. Bacteria were identified at each stage using 16S rDNA PCR amplification and sequence phylogeny.

Results

There was no evidence of bacterial cross-contamination from patients to the laboratory. The current process of disinfection of impression appears to be adequate. Contamination was found on the final removable appliances (0.97 × 102–1.52 × 103 cfu ml−1), and this contamination occurred from within the laboratory itself.

Conclusions

Every effort is made to reduce potential cross-infection to patients and dental professionals. Newly constructed removable appliances were shown not to be free from contamination with bacteria prior to clinical use, but this contamination is environmental. Further studies would be required to determine the level of risk this poses to patients.

Clinical significance

Dental professionals have a duty of care to minimise or eradicate potential risks of cross-infection to patients and other members of the team. To date, much less attention has been paid to contamination from the orthodontic laboratory, so contamination and infection risks are unknown.

Tuesday, November 18, 2014

Effect of periodontal treatment on peak serum levels of inflammatory markers

, Volume 18, Issue 9, pp 2113-2121

Abstract

Background and objective

Some subjects with untreated periodontitis exhibit elevated levels of distinct inflammatory markers in serum. The aim of the study was to assess whether nonsurgical periodontal therapy changes the levels of these markers and lowers these peaks.

Methods

Forty periodontally diseased subjects received nonsurgical periodontal therapy (full-mouth scaling and root planing within 48 h) with either adjunctive systemic amoxicillin and metronidazole (n = 19) or placebo (n  = 21). Serum samples, obtained at baseline (BL) and 3 months after treatment (M3), were evaluated for 15 cytokines and 9 acute-phase proteins using the Bio-Plex bead array multianalyte detection system. For each analyte, peak values were defined as greater than the mean + 2 standard deviations (SD) of measurements found in 40 periodontally healthy persons. Proportions were compared using Fisher’s exact test.

Results

At M3, a significantly better primary clinical outcome (persisting pockets of >4 mm with bleeding on probing) was obtained in patients treated with scaling and root planing plus antibiotics compared to those receiving placebo (3.3 ± 5.1 vs. 6.8 ± 7.8 pockets per patient, p  < 0.05). The levels of cytokines and acute-phase proteins of periodontitis patients were usually below the mean + 2 SD threshold of healthy persons. However, values above threshold were found in some individuals. Eleven patients showed a peak value of one analyte, and seven patients showed two peaks. In the remaining 12 patients, between three and ten analytes showed peak values. Therapy greatly reduced the number of subjects with four or more peaks (BL, 11 subjects; M3, 1 subject, p = 0.003). With regards to the reduction of peaks, no specific benefit of adjunctive antibiotics could be seen.

Conclusion

Subjects with untreated periodontitis may show high peaks for several inflammatory markers in serum simultaneously. Nonsurgical periodontal treatment with or without antibiotics reduced most of these peak levels.

One-sentence summary

Nonsurgical periodontal treatment with or without antibiotics reduced peak levels of several inflammatory markers in serum of subjects with periodontitis.